Patents Examined by Raymond J. Henley, III
-
Patent number: 11974983Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.Type: GrantFiled: September 22, 2022Date of Patent: May 7, 2024Assignee: Duke UniversityInventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
-
Patent number: 11974998Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.Type: GrantFiled: August 7, 2023Date of Patent: May 7, 2024Assignee: BOW RIVER LLCInventors: Sundar Srinivasan, Christina Chow Wallen
-
Patent number: 11969421Abstract: Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.Type: GrantFiled: June 15, 2022Date of Patent: April 30, 2024Assignee: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Patent number: 11969397Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.Type: GrantFiled: November 7, 2019Date of Patent: April 30, 2024Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Dong-Yun Shin, Jong-Young Choi, Chul-Woo Yang, Sung-Hwan Park, Seon-Yeong Lee, Min-Jung Park, Joo-Yeon Jhun, Se-Young Kim, Hyeon-Beom Seo, Jae-Yoon Ryu, Keun-Hyung Cho
-
Patent number: 11970461Abstract: A 1-hexyl-5-(4-methoxyphenyl)-2,4-diphenyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: December 14, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11964046Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).Type: GrantFiled: May 17, 2017Date of Patent: April 23, 2024Assignee: ALBERTA VETERINARY LABORATORIES LTDInventor: Merle Olson
-
Patent number: 11957688Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.Type: GrantFiled: July 12, 2022Date of Patent: April 16, 2024Assignee: OrphAl Therapeutics Inc.Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
-
Patent number: 11957674Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: January 25, 2022Date of Patent: April 16, 2024Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
-
Patent number: 11957666Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.Type: GrantFiled: September 14, 2021Date of Patent: April 16, 2024Assignee: VELOXIS PHARMACEUTICALS, INC.Inventor: William J. Polvino
-
Patent number: 11950616Abstract: An energy-promoting composition includes an exogenous ketone body component that provides a source of caloric energy, a vasodilator component, a stimulant component, such as caffeine, and optionally a nootropic component. In most if not all cases, the vasodilator, stimulant, and nootropic components do not themselves provide a source of caloric energy but may increase metabolism of available caloric energy. The separate components beneficially and synergistically interact with one another to enhance the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks.Type: GrantFiled: May 14, 2021Date of Patent: April 9, 2024Assignee: AXCESS GLOBAL SCIENCES, LLCInventor: Gary Millet
-
Patent number: 11952634Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.Type: GrantFiled: November 10, 2021Date of Patent: April 9, 2024Assignee: Medivation Prostate Therapeutics LLCInventors: Amy Christian Peterson, Hirdesh Uppal
-
Patent number: 11945779Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer metastasis, a health functional food, and a method for preventing or treating cancer metastasis using the same, containing a novel compound for inhibiting migration and invasion of cancer cells or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: May 2, 2019Date of Patent: April 2, 2024Assignee: VSPHARMTECHInventors: Byoung-Mog Kwon, Dong Cho Han, Yae Jin Yoon, Yu Jin Lee, Jiyoun Choi, Sangku Lee
-
Patent number: 11944683Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: GrantFiled: March 17, 2023Date of Patent: April 2, 2024Assignee: Axsome Therapeutics, Inc.Inventor: Herriot Tabuteau
-
Patent number: 11939347Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: June 23, 2021Date of Patent: March 26, 2024Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich
-
Patent number: 11939285Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.Type: GrantFiled: October 29, 2021Date of Patent: March 26, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES, INC.Inventor: Roger D. Tung
-
Patent number: 11925651Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: August 2, 2022Date of Patent: March 12, 2024Assignee: Ikena Oncology, Inc.Inventor: Alfredo C. Castro
-
Patent number: 11918585Abstract: The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.Type: GrantFiled: December 28, 2021Date of Patent: March 5, 2024Assignee: Incyte CorporationInventors: William L. Rocco, Francis X. Muller
-
Patent number: 11919912Abstract: Provided are novel compounds of Formula (I): Formula (I); and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.Type: GrantFiled: May 17, 2019Date of Patent: March 5, 2024Assignee: Constellation Pharmaceuticals, Inc.Inventors: Alexandre Côté, Avinash Khanna, Ludivine Moine
-
Patent number: 11911382Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.Type: GrantFiled: July 18, 2022Date of Patent: February 27, 2024Assignee: Altavant Sciences GmbHInventors: Steve Wring, Magdalena Alonso-Galicia, Thomas Pack, Julie Rurka, David Carpenter, Melissa Rhodes
-
Patent number: 11903938Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.Type: GrantFiled: March 26, 2021Date of Patent: February 20, 2024Assignee: Amicus Therapeutics, Inc.Inventors: Jeff Castelli, Elfrida Benjamin